Source: Telescope Innovations Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Telescope Innovations Corp. (TELI) has completed a four-month feasibility project funded by Pfizer (PFE) to explore accelerating pharmaceutical process development through automation
  • The company created a proof-of-concept robotic to help accelerate the translation of newly identified chemistry, processes, and materials from initial discovery to scaled-up commercial deployment
  • Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry
  • Telescope Innovations Corp. (TELI) is trading steady at $0.35 per share as of 10:10 am ET

Telescope Innovations (TELI) has completed a four-month feasibility project to explore accelerating pharmaceutical process development through automation.

The project was funded by Pfizer (PFE).

The company created a proof-of-concept robotic workflow leveraging its proprietary in-situ analytical technology and automation tools and examined how the proof-of-concept platform could evolve over the next decade.

The platform is designed to help accelerate the translation of newly identified chemistry, processes, and materials from initial discovery to scaled-up commercial deployment.

Telescope CEO Jason Hein stated that high-quality data is the key to unlock the potential of these tools to enable companies to achieve faster product discovery and development.

“Deploying our automation and analytical platforms to support the pharmaceutical industry is a key strategic aim for Telescope.”

Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry.

Telescope Innovations Corp. (TELI) is trading steady at $0.35 per share as of 10:10 am ET.


More From The Market Herald
VitalHub

" VitalHub (TSX:VHI) announces multi year contract with NHS Mid and South Essex ICB

VitalHub (VHI) announced a multi-year licensing contract with NHS Mid and South Essex Integrated Care Board (Essex).
Resverlogix Corp. - SVP of Clinical Development, Dr. Michael Sweeney.

" Resverlogix (TSX:RVX) focuses drug development on COVID-19

Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.